Japan PMDA Device Landscape: 88,900 Approved Products and MAH Concentration

Executive Summary

Japan is one of the world's largest medical device markets — valued at roughly $32–38 billion (2023) and consistently ranked among the world's three to four largest, behind the United States — and one of its most distinctive regulatory environments, because every approved device must be held and marketed by a Japanese legal entity known as a Marketing Authorization Holder (MAH). Our analysis of the Pharmaceuticals and Medical Devices Agency (PMDA) medical device database finds approximately 88,900 approved and certified medical-device products as of June 2026, marketed through 2,796 distinct MAHs.

Three structural findings define the Japanese device landscape:

1. The product base is large and broad. Across 88,973 unique approval/certification numbers, Japanese regulators have approved one of the deepest medical-device portfolios of any single market — spanning everything from dental consumables and surgical instruments to implantable cardiovascular devices and advanced imaging systems.
2. Concentration is led by domestic Japanese MAHs, not global majors. The top 10 MAHs hold 20.4% of the current active package-insert base, and the top 50 hold 40.8%. The leaders are predominantly Japanese specialty manufacturers and distributors (KSI, Tana Medical Instruments, Fujiflex, Mizuho) rather than the global brand owners, because Japan's MAH model requires a local legal entity to hold each licence.
3. A 2021 regulatory mandate reshaped the public dataset. Current package inserts dated 2021 outnumber any other year by a wide margin, reflecting the August 2021 electronic package-insert (e-IFU) mandate — the deadline by which manufacturers had to publish current Japanese package inserts (IFUs) electronically on PMDA's website — not a surge of brand-new approvals.

This article breaks down the Japanese device landscape by MAH concentration, package-insert vintage, and document type — giving regulatory strategists and market-access teams a quantitative foundation for Japan planning.

Data Source and Methodology

All statistics in this article are derived from our direct analysis of the PMDA medical device database (public extract dated 7 June 2026). PMDA publishes, for each approved or certified device, the associated regulatory documents — most importantly the package insert (IFU / 添付文書) and review reports — as downloadable PDFs. Our dataset comprises 269,816 document records spanning the non-drug (medical-device) product set.

To move from documents to devices, we deduplicated on the approval or certification number — the unique identifier assigned to each approved or certified product — yielding 88,973 unique products. Marketing Authorization Holder (manufacturer) concentration was computed against the 111,994 records tagged as the current package-insert version (current_pdf), which represents the active in-market package-insert base. Package-insert vintage was derived from the date marked on each current insert. MAH concentration was computed using standard Herfindahl-Hirschman Index (HHI) methodology. MAH names appear in Japanese in the source; this article provides English identifications (transliterated company names alongside the global-brand entities where applicable).

Note on interpretation: PMDA's database is document-centric rather than a single row-per-device register. A given product can carry multiple documents (current and historical package inserts, review reports, safety notices). We therefore report the unique-product count (88,973) for the approved-product universe and the current package-insert base (111,994) for MAH concentration and vintage analysis.

Japan's Regulatory Framework: The MAH Model

Japan regulates medical devices under the Pharmaceuticals and Medical Devices Act (PMD Act), which came into effect on 25 November 2014 and replaced the earlier Pharmaceutical Affairs Law (PAL). The PMD Act is administered by the Ministry of Health, Labour and Welfare (MHLW), with the Pharmaceuticals and Medical Devices Agency (PMDA) conducting scientific reviews.

A central feature of the PMD Act is the Marketing Authorization Holder (MAH) system. Under this model, a Japanese legal entity — not the foreign manufacturer — must obtain Marketing Authorization and bear legal responsibility for each device placed on the Japanese market. The MAH is responsible for quality management (under the QMS Ordinance, MHLW Ordinance No. 169, based on ISO 13485) and post-market safety management (under the Good Vigilance Practice, GVP, Ordinance). Foreign manufacturers typically engage a Designated MAH (DMAH) or a local distributor to serve this role; they cannot market devices directly in Japan.

The pathway a device takes depends on its risk class:

This is why MAH concentration in the data is led by Japanese entities: by law, every one of the ~88,900 products is held by a Japanese MAH, whether that MAH is a domestic specialty manufacturer, a domestic distributor, or the Japan subsidiary of a global brand.

MAH Concentration: Who Holds Japan's Device Licences

Among the current active package-insert base, there are 2,796 distinct MAHs. The distribution is skewed toward a layer of Japanese specialty manufacturers and distributors, with the Japan subsidiaries of global brands appearing further down:

Concentration metrics:

• Top 5 MAHs: 17,240 current inserts (15.4%)
• Top 10 MAHs: 22,829 current inserts (20.4%)
• Top 20 MAHs: 31,246 current inserts (27.9%)
• Top 50 MAHs: 45,693 current inserts (40.8%)
• HHI: 79 (moderate, fragmented)

An HHI of 79 indicates a competitively fragmented MAH landscape — well below the 2,500 high-concentration threshold. Yet two structural features stand out. First, the top of the table is dominated by domestic Japanese specialty MAHs and distributors rather than the global brand owners whose products ultimately reach patients. Companies such as KSI, Tana Medical Instruments, and Fujiflex are large domestic holders that aggregate broad portfolios of instruments and consumables; Mizuho is a long-established surgical-table and operating-room-equipment manufacturer; Inami is a historic ophthalmic-instrument maker; and Shiai Medical and O-mic serve the dental and specialty segments. Second, the Japan subsidiaries of global majors appear in the next tier — Fujifilm (imaging and endoscopy), Johnson & Johnson (surgical and orthopedics), Olympus Medical Systems (endoscopy, ~978 inserts), Stryker Japan (~932), and Zimmer Biomet G.K. (~880).

The implication is structural and important for foreign manufacturers: the MAH that holds a product's Japanese licence is very often a domestic Japanese entity rather than the foreign brand owner's own subsidiary. Two factors drive this. First, Japan retains a substantial domestic manufacturing base, and the largest MAHs (KSI, Tana Medical Instruments, Fujiflex, Mizuho, Inami) are domestic Japanese manufacturers and specialty distributors holding their own and aggregated portfolios — not merely importers. Because these portfolios span thousands of instruments, consumables, and dental products, they dominate the insert-count-based concentration table. Second, for imported products — which by value supply roughly two-thirds of Japan's medical-device market (MHLW and trade data put 2023 imports at about $23.6B against a ~$34.7B market) — the distributor/DMAH model dominates: foreign manufacturers engage a Japanese MAH to register, hold, and market their devices, a relationship with significant regulatory, commercial, and post-market implications. Under the revised PMD Act, the older in-country-caretaker model was replaced by the MAH/DMAH system; the MAH must hold a business license (KYOKA) from MHLW, and foreign manufacturing sites must be registered through the Foreign Manufacturer Registration (FMRS) process.

Package-Insert Vintage: The 2021 Electronic-IFU Mandate

The vintage distribution of current package inserts shows a striking and easily misread feature — a large 2021 cluster:

The 2021 count (36,973 current inserts) is roughly three times the volume of any other recent year, and it requires careful interpretation. This is not a sign that 36,973 devices were newly approved in 2021. Rather, it reflects the 1 August 2021 electronic package-insert (e-IFU) mandate — a 2019 PMD Act amendment under which manufacturers were required to publish current Japanese package inserts (IFUs) electronically on PMDA's Medical Device Safety Information Posting System (the system links each product's GS1 barcode to its e-leaflet). To comply, manufacturers submitted current-version package inserts for large numbers of already-approved products, and those compliant inserts carry a 2021 marking. In effect, the 2021 cluster is a regulatory-housekeeping signature — a one-time bulge created by the e-publication mandate — superimposed on the underlying flow of genuine new approvals and revisions.

Excluding the 2021 mandate bulge, current-package-insert volume has settled into a steady 12,000–15,000 per year (2022–2025), with 2025 reaching a recent high of 15,052. This stable run-rate reflects the combined activity of new Class II certifications and Class III/IV approvals, ongoing package-insert revisions, and the maturation of Japan's electronic-postmarket information infrastructure.

Document Composition

The PMDA database contains several document types beyond the package insert. Package inserts (添付文書) are by far the largest category, but the dataset also captures safety information, review reports, and revision-notice records:

The dominance of package inserts reflects their role as the core regulatory document for each device, and the volume of safety-information and revision-directive records underscores the intensity of Japan's post-market surveillance and label-revision activity — an ongoing obligation for every MAH.

Japan in Regional and Global Context

Japan's MAH model makes its device market structurally different from reliance-based or registrant-based markets elsewhere in Asia. In Singapore, Malaysia, or South Korea, a local registrant or license holder is required, but the global brand owner typically retains a more direct relationship to the registration. In Japan, the MAH is a fuller legal and operational role — it must maintain QMS and GVP compliance, hold the approval, and bear liability — which is why the concentration table is led by domestic Japanese entities even for globally branded products.

For market-access teams, three practical conclusions follow from the data:

1. The MAH choice is the central market-access decision in Japan. Because the MAH holds the licence and bears regulatory responsibility, foreign manufacturers must select a DMAH or distributor-partner MAH with durable QMS/GVP infrastructure — not merely a registration agent.
2. The market is fragmented enough to offer options. An HHI of 79 and nearly 2,800 active MAHs mean there are many capable local holders; competitive entry is feasible across most device categories.
3. Plan for the electronic-postmarket regime. The 2021 electronic-package-insert (e-IFU) mandate is now an established obligation, and every new approval must be accompanied by a Japanese package insert published on PMDA's system.

Key Takeaways

• ~88,900 approved and certified medical-device products (88,973 unique approval/certification numbers) marketed through 2,796 MAHs as of June 2026
• MAH concentration is moderate (HHI 79); the top 50 MAHs hold 40.8% of the current package-insert base
• Domestic Japanese MAHs lead the concentration table (KSI 5.3%, Tana Medical Instruments 3.4%, Fujiflex 3.2%, Mizuho 2.3%), with global majors' Japan subsidiaries (Fujifilm, J&J, Olympus, Stryker Japan, Zimmer Biomet) in the next tier
• A large 2021 package-insert cluster (36,973) reflects the August 2021 electronic package-insert (e-IFU) mandate — a regulatory-housekeeping signature, not a surge of new approvals
• The PMD Act MAH model requires a Japanese legal entity to hold every licence, making the MAH/DMAH choice the central market-access decision for foreign manufacturers
• Steady 12,000–15,000 current package inserts per year (2022–2025) reflect ongoing certifications, approvals, and revisions

Data Source

Analysis sample: PMDA medical device database (public extract dated 7 June 2026), 269,816 document records across the non-drug (medical-device) product set. Unique-product count (88,973) derived by deduplication on approval/certification number. MAH concentration computed against the 111,994 current package-insert records via HHI across all 2,796 MAHs. Package-insert vintage derived from insert date marking. MAH names identified/transliterated from Japanese. Regulatory framework, market size, import share, and the August 2021 electronic-IFU (e-package-insert) mandate sourced from the PMD Act, PMDA/MHLW, the US International Trade Administration, Pure Global, Emergo by UL, Freyr Solutions, the Johner Institute, and Jones Day. All numbers reflect the public database and may differ slightly from PMDA's internal records due to the timing of data publication and the document-centric structure of the source.